-The Business Standard State must get out of insulin price-setting The National Pharmaceutical Pricing Authority, or NPPA, has turned down the request of drug companies to raise insulin prices. Domestic insulin-makers Biocon and Cadila had argued that the cost of production and packaging had become higher, and multinational corporation Eli Lilly wanted the depreciation in the rupee vis-à-vis the dollar to be factored into the price. The NPPA says it has...
More »SEARCH RESULT
Dogged with corruption, drug regulation is in poor health and ineffective-Khomba Singh
-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...
More »Cheap generics no panacea for India's poorest
-Reuters Cheap generic drugs were meant to change the life of Nandakhu Nissar, whose mouth is swollen by a cancerous tumour. But the cashless and hungry 55-year-old sleeps on a pavement staring up at the windows of Mumbai's biggest cancer hospital. "What is a generic drug?" shrugs Nissar, who has travelled over 1,500 kms (900 miles) from his home in the hope of treatment. "I have borrowed money from friends and relatives...
More »Faulty formula by Ankur Paliwal
New drug pricing policy proposes bringing all essential medicines under price control, but makes them expensive After years of dilly-dallying and several Supreme Court reminders, the Centre has proposed to bring all essential drugs under price control. But the policy is nothing but hogwash. Its pricing mechanism would make essential medicines out of reach for most people. Public health experts have termed the draft National Pharmaceutical Pricing Policy of 2011 a...
More »New pharma policy to cap prices of 60% drugs by Namrata Nandakumar & CH Unnikrishnan
India’s new pharmaceutical policy seeks to bring at least 400 essential medicines—or 60% of the drugs sold in the country—under the government’s pricing control. The department of pharmaceuticals on Friday put out a draft policy, pending since 2005, after a committee prepared a list of essential medicines, laying down new rules governing drug pricing. Currently, the government controls the prices of only 34 essential medicines. The draft says the policy, to be finalized...
More »